These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 30784614)

  • 1. Incretin Physiology and Pharmacology in the Intensive Care Unit.
    Plummer MP; Hermanides J; Deane AM
    Crit Care Clin; 2019 Apr; 35(2):341-355. PubMed ID: 30784614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes.
    Wu T; Little TJ; Bound MJ; Borg M; Zhang X; Deacon CF; Horowitz M; Jones KL; Rayner CK
    Diabetes Care; 2016 Apr; 39(4):511-7. PubMed ID: 26786576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incretin-based therapy of type 2 diabetes mellitus.
    Knop FK; Vilsbøll T; Holst JJ
    Curr Protein Pept Sci; 2009 Feb; 10(1):46-55. PubMed ID: 19275672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes.
    Mentis N; Vardarli I; Köthe LD; Holst JJ; Deacon CF; Theodorakis M; Meier JJ; Nauck MA
    Diabetes; 2011 Apr; 60(4):1270-6. PubMed ID: 21330636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
    Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
    Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The incretin effect in critically ill patients: a case-control study.
    Nielsen ST; Janum S; Krogh-Madsen R; Solomon TP; Møller K
    Crit Care; 2015 Nov; 19():402. PubMed ID: 26567860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
    Siddiqui NI
    Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RD Lawrence Lecture 2017 Incretins: the intelligent hormones in diabetes.
    Gault VA
    Diabet Med; 2018 Jan; 35(1):33-40. PubMed ID: 29044772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose cotransporter-2 inhibition improves incretin sensitivity of pancreatic β-cells in people with type 2 diabetes.
    Ahn CH; Oh TJ; Kwak SH; Cho YM
    Diabetes Obes Metab; 2018 Feb; 20(2):370-377. PubMed ID: 28786557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin.
    Wu T; Ma J; Bound MJ; Checklin H; Deacon CF; Jones KL; Horowitz M; Rayner CK
    Diabetes; 2014 Aug; 63(8):2776-87. PubMed ID: 24647737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
    Hansotia T; Drucker DJ
    Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incretin hormone mimetics and analogues in diabetes therapeutics.
    Green BD; Flatt PR
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):497-516. PubMed ID: 18054732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?
    Van Gaal LF; Gutkin SW; Nauck MA
    Eur J Endocrinol; 2008 Jun; 158(6):773-84. PubMed ID: 18322302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response.
    Tura A; Bagger JI; Ferrannini E; Holst JJ; Knop FK; Vilsbøll T; Mari A
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1123-1129. PubMed ID: 29162361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on incretin hormones.
    Phillips LK; Prins JB
    Ann N Y Acad Sci; 2011 Dec; 1243():E55-74. PubMed ID: 22545749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic enzyme supplementation improves the incretin hormone response and attenuates postprandial glycemia in adolescents with cystic fibrosis: a randomized crossover trial.
    Perano SJ; Couper JJ; Horowitz M; Martin AJ; Kritas S; Sullivan T; Rayner CK
    J Clin Endocrinol Metab; 2014 Jul; 99(7):2486-93. PubMed ID: 24670086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Incretins on Insulin Function and Glucose Homeostasis.
    Holst JJ; Gasbjerg LS; Rosenkilde MM
    Endocrinology; 2021 Jul; 162(7):. PubMed ID: 33782700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postprandial responses of incretin and pancreatic hormones in non-diabetic patients with end-stage renal disease.
    Idorn T; Knop FK; Jørgensen M; Holst JJ; Hornum M; Feldt-Rasmussen B
    Nephrol Dial Transplant; 2014 Jan; 29(1):119-27. PubMed ID: 24078334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.